METABOMED
Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly and result in a higher likelihood of a successful treatment.
METABOMED
Industry:
Biopharma Biotechnology Health Care Life Science Medical
Founded:
2014-01-01
Address:
Yavne, HaMerkaz, Israel
Country:
Israel
Website Url:
http://www.metabomed.com
Total Employee:
1+
Status:
Active
Total Funding:
30.5 M USD
Technology used in webpage:
Microsoft Azure DNS ASP.NET IIS ASP.NET 4.0 IIS 8 Hetzner Adobe Enterprise Cloud Symantec.cloud Entrust SSL Adobe Sign
Similar Organizations
Tierra Biosciences
Tierra Biosciences is a synthetic biology company that offers an AI-driven platform with a vast range of custom proteins for research.
Current Advisors List
Current Employees Featured
Founder
Investors List
Arkin Bio Ventures
Arkin Bio Ventures investment in Series B - Metabomed
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series B - Metabomed
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Metabomed
Yonjin Venture
Yonjin Venture investment in Series B - Metabomed
Pontifax
Pontifax investment in Series B - Metabomed
Arkin Holdings
Arkin Holdings investment in Series A - Metabomed
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Series A - Metabomed
M Ventures
M Ventures investment in Series A - Metabomed
Pontifax
Pontifax investment in Series A - Metabomed
Pfizer
Pfizer investment in Series A - Metabomed
Official Site Inspections
http://www.metabomed.com
- Host name: mail.cloudhost.co.il
- IP address: 192.117.187.254
- Location: Tel Aviv Israel
- Latitude: 32.0678
- Longitude: 34.7647
- Timezone: Asia/Jerusalem
More informations about "Metabomed"
Metabomed - Crunchbase Company Profile & Funding
Metabomed designs drugs designed treats cancer. Its drugs target the reprogrammed cancer cell's metabolism to halt their growth, enabling patients to begin their treatment more quickly …See details»
Metabomed Company Profile - Office Locations, Competitors
Sep 9, 2020 · Metabomed is a drug discovery company in the field of cancer metabolism. The Company is developing a proprietary target identification platform based on computational …See details»
Metabomed Company Profile 2024: Valuation, Funding
Operator of a drug discovery company intended to assist in the field of cancer metabolism.See details»
Metabomed Ltd. - LinkedIn
Metabomed Ltd. | 578 followers on LinkedIn. Metabomed is a drug discovery company in the field of cancer metabolism. The Company is developing a proprietary target identification platform...See details»
Cancer Metabolism Company Metabomed Completes $18 Million …
Apr 4, 2016 · Metabomed is focusing on the discovery and development of potential small molecule drugs directed against novel targets in the field of cancer metabolism.See details»
Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 ...
Information on acquisition, funding, investors, and executives for Metabomed (Portfolio of Small Molecule Acetyl Co-A Synthetase-2 Inhibitor). Use the PitchBook Platform to explore the full …See details»
Metabomed Ltd. - VentureRadar
Metabomed is developing a therapeutic strategy based on new drugs that inhibit metabolic enzymes which are vital for cancer cells’ survival. Metabomed identifies reprogrammed …See details»
Metabomed - Products, Competitors, Financials, Employees, …
Metabomed is a drug discovery company in the field of cancer metabolism with a proprietary target identification platform based on computational biology and metabolomics. Use the CB …See details»
Cancer Metabolism Company Metabomed Completes $18 Million …
Metabomed is focusing on the discovery and development of potential small molecule drugs directed against novel targets in the field of cancer metabolism.See details»
Metabomed Completes a $12.5 Million Raise in Order to Advance …
Dec 19, 2019 · YAVNE, Israel and CAMBRIDGE, Massachusetts, Dec. 19, 2019 /PRNewswire/ -- Metabomed, a leading cancer metabolism company completed a financing of $12.5 million …See details»
Metabomed - Foreign Startup | Startup Nation Finder
Apr 4, 2016 · Metabomed is a drug-discovery company in the field of cancer metabolism, with a proprietary target-identification platform based on computational biology and metabolomics. …See details»
Metabomed - Contacts, Employees, Board Members, Advisors
Metabomed designs drugs that treats cancer. Start Free Trial . Chrome ExtensionSee details»
Cancer Metabolism Company Metabomed Completes $18 Million …
Apr 4, 2016 · Israeli cancer metabolism company Metabomed LTD. announced today that it has completed an extension of its Series A round from current and new investors, bringing the total …See details»
MetaboMed Appoints Ali Fattaey, Ph.D. as Chief Executive Officer
Sep 9, 2020 · CAMBRIDGE, Mass. and YAVNE, Israel, Sept. 9, 2020 /PRNewswire/ -- MetaboMed, a biopharmaceutical company focused on discovering and developing novel …See details»
Israeli Cancer Startup catches Investment of 3 Big Pharma
Apr 5, 2016 · Metabomed is developing new highly-selective drugs that target cancer metabolism - and has now raised €15.8M and gotten a new CEO from Merck's ranks.See details»
Targeted cancer therapy co Metabomed raises $12.5m - Globes
Dec 19, 2019 · Israeli drug discovery cancer metabolism company Metabomed has completed a $12.5 million financing round led by Yonjin Venture, and with the participation of all its existing …See details»
Clinical Trial: NCT04990739 - My Cancer Genome
MetaboMed is developing MTB-9655, an orally bioavailable, first-in-class small molecule inhibitor of the human Acetyl coenzyme A (Acyl-CoA) synthetase short chain family member 2 …See details»
EpiVario Announces Acquisition of Acetyl CoA Synthetase 2 …
PHILADELPHIA, Jan. 16, 2024 /PRNewswire/ -- EpiVario Inc., a biotech company pioneering neuroepigenetics to treat addiction disorders, today announced that it has entered into an …See details»
Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ...
Jun 2, 2022 · MTB-9655 is a potent (IC 50 = 0.15nM in biochemical, and EC 50 = 3nM in cellular assays) oral inhibitor of ACSS2 and induces anti-tumor effects in xenograft mouse models of …See details»